We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Applied Biosystems/MDS Sciex Mass Spectrometer Cuts Costs for Therapeutic Drug Monitoring

Read time: Less than a minute

Scientists from the Department of Clinical Chemistry at the George August University, Germany, are using an Applied Biosystems/MDS Sciex API 2000™ LC/MS/MS System to research and develop methods for routine therapeutic drug monitoring.

Prof Dr Michael Oellerich, Head of the Department of Clinical Chemistry, explained, "We started using this system over six years ago, when we developed a very elegant tandem MS method for the simultaneous determination of various immunosuppressive drugs such as sirolimus, everolimus, tacrolimus and cyclosporin in whole blood."

"It is also used for determination of total and free plasma concentrations of mycophenolic acid and its metabolites in pharmacokinetic studies."

"I am very happy with the API 2000 System; it is robust and reliable and we have practically no relevant down time with our two systems. Using LC/MS/MS, we can simultaneously determine several compounds and we have a sufficient throughput with at least 50 per cent fewer direct costs!"

"Furthermore, we can work with very low limits of quantification, with very high precision and specificity, far better than immunoassays."

"We are always refining the process, for example, we are now using solid phase extraction with the big advantage that there is less ion suppression. This means we can shorten the run time dramatically, from 4 minutes to about 2 minutes."

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.